Sanada T, et al. - Researchers investigated lysyl oxidase like 2 (LOXL2) expression levels in human serum from head and neck squamous cell carcinoma (HNSCC) patients to assess if LOXL2 was worth further evaluation. For this case series study, LOXL2 protein levels in three serum samples from HNSCC patients were evaluated by immunoblotting and LOXL2 tissue expression was analyzed in one human tongue squamous cell carcinoma (SCC) tissue by immunohistochemistry as a representative of HNSCC tissue. Statistical analysis showed a link between elevated serum exosomal LOXL2 levels and low-grade, but not high-grade, HNSCC. Roughly threefold higher levels of LOXL2 were found in HNSCC patients vs three healthy volunteers. In order to determine the potential clinical utility of LOXL2 as a new biomarker and/or therapy target for HNSCCs, a large cohort clinical study will be needed.